CD8A and neoplasm: Moreover, tumor-derived EVs suppress anti-tumor immune responses by hindering CD8+ T cell proliferation and activation, promoting regulatory T cell and myeloid-derived suppressor cell expansion, impairing natural killer cell function, disrupting monocyte differentiation, and inducing dysfunction and exhaustion in T cells, ultimately facilitating immune evasion and the development of drug resistance associated with cancer therapy [74,75].